Description
The main goal of Riseup-PPD COST Action is to establish a Pan-European multidisciplinary network of researchers dedicated to the understanding of Peripartum Depression Disorder (PPD), from its prevention and assessment to its treatment and global impact.
Currently available European estimates, show that PPD prevalence ranges from 4% to 38%, carrying several consequences for women, newborns-infants, and family systems, representing a socioeconomic burden to society.
Riseup-PPD aims at filling gaps in PPD research, practice and social awareness by developing updated reviews fostering research efforts on the standardization of diagnostic criteria, the development of adequate screening tools and cost-effectiveness evaluation of prevention and treatment programs. Additionally, the Action seeks to bridge multidisciplinary knowledge on the determinants of depressive symptoms in the peripartum period, and the mechanisms of action and change. This will be achieved by supporting a network capable of conducting innovative, translational projects on the neuropsychological mechanisms and biomarkers involved in the onset, maintenance and impact of PPD on women, newborns-infants and families, combined with cost-effectiveness analysis and evidence-based and implementation research projects. Finally, Riseup-PPD aims at building a shared database providing research teams with large quality-controlled datasets.
Ultimately, the network will boost new implications for clinical practice, increasing cost-effectiveness and promoting the quality of innovative health care services in PPD, reaching a real impact on end-users.
Riseup-PPD will strengthen Europe’s leading position in PPD by means of a network that supports Early Career Investigators, particularly from Inclusiveness Target Countries and female researchers, assuring a geographical and gender balanced Pan-European network.
Action keywords
Peripartum Depression Disorder - Women’s Mental Health - Newborn Development - Individualized Interventions - International Database
Management Committee
Country | MC Member |
---|---|
Albania | |
Albania | |
Austria | |
Austria | |
Belgium | |
Belgium | |
Bosnia and Herzegovina | |
Bosnia and Herzegovina | |
Bulgaria | |
Croatia | |
Croatia | |
Cyprus | |
Denmark | |
Denmark | |
Estonia | |
Estonia | |
Finland | |
Finland | |
France | |
France | |
Germany | |
Germany | |
Greece | |
Greece | |
Ireland | |
Ireland | |
Israel | |
Israel | |
Italy | |
Italy | |
Latvia | |
Latvia | |
Malta | |
Malta | |
Netherlands | |
North Macedonia | |
Norway | |
Norway | |
Poland | |
Poland | |
Portugal | |
Portugal | |
Serbia | |
Serbia | |
Slovenia | |
Slovenia | |
Spain | |
Sweden | |
Sweden | |
Switzerland | |
Türkiye | |
Türkiye | |
United Kingdom |
Main Contacts
Action Contacts
COST Staff
Leadership
Role | Leader |
---|---|
Action Chair | |
Action Vice-Chair | |
Grant Holder Scientific Representative | |
Grant Awarding Coordinator | |
WG1 Leader | |
WG2 Leader | |
WG3 Leader | |
WG4 Leader | |
WG5 Leader | |
WG6 Leader |
Additional roles
Role | Leader |
---|---|
Working Group 1 Co-Leader | |
Working Group 2 Co-Leader | |
Working Group 3 Co-Leader | |
Working Group 5 Co-Leader | |
Working Group 6 Co-Leader | |
Taskforce "Perinatal Mental Health and COVID-19 Pandemic" Leader | |
Taskforce "Perinatal Mental Health and COVID-19 Pandemic" Co-Leader | |
Gender-balance and Young Researchers Coordinator | |
Training Schools and Workshops Coordinator | |
Publications Committee Coordinator | |
Working Group 1 Subgroup 1 Leader | |
Working Group 1 Subgroup 2 Leader | |
Working Group 1 Subgroup 3A Leader | |
Working Group 1 Subgroup 3B Leader | |
Working Group 1 Subgroup 4 Leader | |
Working Group 1 Subgroup 5 Leader | |
Working Group 2 Subgroup 1 Leader | |
Working Group 2 Subgroup 2 Leader | |
Working Group 2 Subgroup 3 Leader | |
Working Group 2 Subgroup 4 Leader | |
Virtual Networking Support Manager | |
Clinical Guidelines Development Group Coordinator | |
ITC CG Coordinator | |
STSM Coordinator |
Working Groups
Number | Title | Leader |
---|---|---|
1 | Prevention and Treatment strategies in PPD | |
2 | Assessment approaches and methods in PPD | |
3 | Neuroimaging and neurophysiological approaches and methods in PPD | |
4 | Ethical standards and procedures for clinical research in PPD | |
5 | Data sharing and data management in PPD | |
6 | Inclusiveness, Dissemination and Public Engagement |
Membership
Name | Working Group | Country |
---|---|---|
WG 1 | Ireland | |
WG 1 | Italy | |
WG 1 | Albania | |
WG 1 | Cyprus | |
WG 1 | Bulgaria | |
WG 1, WG 3 | Austria | |
WG 1 | United Kingdom | |
WG 1, WG 6 | Greece | |
WG 1 | Albania | |
WG 1 | Malta | |
WG 1 | ||
WG 1 | France | |
WG 1, WG 6 | Türkiye | |
WG 1 | France | |
WG 1 | Serbia | |
WG 1, WG 2 | Estonia | |
WG 1 | Switzerland | |
WG 1 | Poland | |
WG 1 | ||
WG 1 | Spain | |
WG 1, WG 2, WG 3 | Belgium | |
WG 1, WG 2, WG 3 | Austria | |
WG 1 | Netherlands | |
WG 1 | ||
WG 1 | Israel | |
WG 1 | Israel | |
WG 1 | Croatia | |
WG 1 | Poland | |
WG 1 | Bosnia & Herzegovina | |
WG 1 | Serbia | |
WG 1 | Croatia | |
WG 1, WG 2 | North Macedonia | |
WG 1, WG 2 | ||
WG 1 | Spain | |
WG 1 | ||
WG 1 | Italy | |
WG 1 | Türkiye | |
WG 1, WG 2 | Italy | |
WG 1 | Spain | |
WG 1 | Portugal | |
WG 1 | Portugal | |
WG 1, WG 2, WG 3 | Portugal | |
WG 1 | Serbia | |
WG 1, WG 2 | Spain | |
WG 1, WG 5 | Germany | |
WG 1 | ||
WG 1, WG 6 | Croatia | |
WG 1 | ||
WG 1 | Norway | |
WG 1 | ||
WG 1, WG 2 | ||
WG 1 | ||
WG 1 | Portugal | |
WG 1, WG 2 | Spain | |
WG 1, WG 6 | ||
WG 1 | Türkiye | |
WG 1 | ||
WG 1, WG 3 | Portugal | |
WG 1, WG 2, WG 3 | ||
WG 1 | Switzerland | |
WG 1 | ||
WG 1, WG 3 | ||
WG 1 | ||
WG 1 | ||
WG 1 | ||
WG 1 | Greece | |
WG 1 | ||
WG 1 | Spain | |
WG 1 | ||
WG 1 | Netherlands | |
WG 1 | ||
WG 1 | Türkiye | |
WG 1, WG 3 | Spain | |
WG 1, WG 5 | Portugal | |
WG 1 | United States | |
WG 1, WG 3 | Brazil | |
WG 1, WG 2 | Türkiye | |
WG 1, WG 3 | Belgium | |
WG 1, WG 2, WG 6 | Portugal | |
WG 1, WG 2 | Sweden | |
WG 1 | ||
WG 1 | Spain | |
WG 1 | Ireland | |
WG 1 | United States | |
WG 1 | Norway | |
WG 1 | Türkiye | |
WG 1 | Ireland | |
WG 1 | Netherlands | |
WG 1 | ||
WG 1 | Türkiye | |
WG 1 | Türkiye | |
WG 1 | ||
WG 1 | Argentina | |
WG 1, WG 3, WG 6 | United Kingdom | |
WG 1 | France | |
WG 1, WG 2, WG 5 | Türkiye | |
WG 1 | United States | |
WG 2 | Portugal | |
WG 2 | Malta | |
WG 2 | Slovenia | |
WG 2, WG 4 | Latvia | |
WG 2 | Slovenia | |
WG 2 | Türkiye | |
WG 2 | Bosnia & Herzegovina | |
WG 2 | Serbia | |
WG 2 | Türkiye | |
WG 2 | Portugal | |
WG 2 | Australia | |
WG 2 | Malta | |
WG 2, WG 3 | Portugal | |
WG 2 | Portugal | |
WG 2, WG 3 | Germany | |
WG 2 | Spain | |
WG 2 | Portugal | |
WG 2 | ||
WG 2, WG 3, WG 6 | Portugal | |
WG 2 | ||
WG 2, WG 4 | Portugal | |
WG 2 | Portugal | |
WG 2 | Belgium | |
WG 2 | Switzerland | |
WG 2 | Sweden | |
WG 2, WG 5 | Spain | |
WG 2, WG 5 | Spain | |
WG 2 | Switzerland | |
WG 2 | Türkiye | |
WG 2 | Sweden | |
WG 2 | Switzerland | |
WG 2, WG 3 | Sweden | |
WG 3 | Germany | |
WG 3 | ||
WG 3 | Portugal | |
WG 3 | ||
WG 3 | ||
WG 3 | ||
WG 3, WG 6 | Ecuador | |
WG 3 | Spain | |
WG 4 | Finland | |
WG 4 | Spain | |
WG 4 | Croatia | |
WG 4, WG 5 | Portugal | |
WG 4, WG 5 | ||
WG 4 | Spain | |
WG 4, WG 5 | Portugal | |
WG 4 | Portugal | |
WG 4 | ||
WG 4 | ||
WG 4 | Portugal | |
WG 4 | Finland | |
WG 4 | Latvia | |
WG 4 | ||
WG 4 | Ireland | |
WG 4 | Portugal | |
WG 4 | Estonia | |
WG 4, WG 6 | Türkiye | |
WG 5 | Germany | |
WG 5 | Portugal | |
WG 5 | ||
WG 5 | Portugal | |
WG 5 | Denmark | |
WG 5 | Denmark | |
WG 5 | Germany | |
WG 5 | Spain | |
WG 5 | Portugal | |
WG 5 | Portugal | |
WG 5 | Spain | |
WG 6 | ||
WG 6 | ||
WG 6 | ||
WG 6 | Croatia | |
WG 6 | Belgium | |
WG 6 | Spain | |
WG 6 | Cyprus | |
WG 6 | Türkiye |